News
BLRX
0.6225
+1.80%
0.0110
Biokine Therapeutics Ltd., BioLineRx Ltd. Granted U.S. Patent #11554159: Compositions And Methods For Treating Cancer
Benzinga · 01/17 16:57
BioLineRx has a new Chief Medical Officer
Seeking Alpha · 01/04 14:10
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 12/29/2022 21:31
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 12/23/2022 13:07
BioLineRx Highlights Early-Stage Trial Data From Cancer Vaccine Candidate
Benzinga · 12/20/2022 17:36
BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors; Study Met Primary Endpoint for Safety and Tolerability
Benzinga · 12/20/2022 12:07
BRIEF-BioLineRx Announces Results From Phase 1/2a Study Of AGI-134
Reuters · 12/20/2022 12:07
BioLineRx Says Phase 1/2a Study of Intratumoral Cancer Vaccine Candidate AGI-134 Meets Primary Endpoint
BioLineRx Says Phase 1/2a Study of Intratumoral Cancer Vaccine Candidate AGI-134 Meets Primary Endpoint
MT Newswires · 12/20/2022 08:42
BLRX: Self-Commercialization in the US
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT Third Quarter 2022 Operational and Financial Results On November 15, 2022, BioLineRx Ltd. (NASDAQ:BLRX) reported 3Q:22 operational and financial results in a press release concurrent ...
Zacks Small Cap Research · 12/05/2022 09:00
BioLineRx to Participate in the 12th Annual LifeSci Partners Corporate Access Event
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that management will participate in the 12th Annual LifeSci Partners Corporate Access Event, taking place January 9-11, 2023, ...
PR Newswire · 11/28/2022 21:30
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 11/21/2022 21:32
biolinerx GAAP EPS of -$0.01
Seekingalpha · 11/15/2022 12:05
BRIEF-Biolinerx Reports Third Quarter 2022 Financial Results
Reuters · 11/15/2022 12:04
BioLine Rx Q3 EPS $(0.01) Beats $(0.11) Estimate. Cash, Cash Equivalents, And Short-Term Bank Deposits of $57.3M
Benzinga · 11/15/2022 12:03
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported third quarter financial results and recent corporate and portfolio updates.
PR Newswire · 11/15/2022 12:00
Notable earnings before Tuesday's open
Seekingalpha · 11/14/2022 15:47
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Benzinga · 11/11/2022 10:10
BioLineRx to Report Third Quarter 2022 Results on November 15, 2022
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended September 30, 2022 on Tuesday, November 15, 2022, before the U.S...
PR Newswire · 11/10/2022 21:30
BioLineRx gets FDA review of stem cell therapy Aphexda for blood cancer patients
Seekingalpha · 11/10/2022 13:29
BRIEF-FDA Accepts Of New Drug Application For Biolinerx's Aphexda In Stem Cell Mobilization
Reuters · 11/10/2022 13:15
More
Webull provides a variety of real-time BLRX stock news. You can receive the latest news about Biolinerx through multiple platforms. This information may help you make smarter investment decisions.
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.